Gungorduk Kemal, Ozdemir Aykut, Ertas Ibrahim E, Gokcu Mehmet, Telli Elcin, Oge Tufan, Sahbaz Ahmet, Sayhan Sevil, Sanci Muzaffer, Harma Mehmet, Ozalp Sinan
Department of Gynecologic Oncology, Tepecik Education and Research Hospital, Izmir, Turkey.
Department of Gynecologic Oncology, Osmangazi University School of Medicine, Eskisehir, Turkey.
Cancer Res Treat. 2015 Apr;47(2):282-9. doi: 10.4143/crt.2014.009. Epub 2014 Sep 4.
The purpose of this study is to evaluate the clinicopathological characteristics, treatment, and prognosis of uterine carcinosarcoma (UC).
A retrospective review of three cancer registry databases in Turkey was conducted for identification of patients diagnosed with UC between January 1, 1996, and December 31, 2012. We collected clinicopathological data in order to evaluate factors important in disease- free survival (DFS) and overall survival (OS).
A total of 66 patients with UC with a median age of 65.0 years were included in the analysis. The median survival time of all patients was 37.5 months and the 5-year OS rate was 59.1%. In early stage patients (I-II) who received adjuvant chemotherapy (CT) with radiation therapy (RT), the median DFS and OS was 44 months and 55 months, respectively, compared to 34.5 months and 36 months, respectively, in patients who received adjuvant RT or CT alone (hazard ratio [HR], 1.4; 95% confidence interval [CI], 0.7 to 3.1 for DFS; p=0.23 and HR, 2.2; 95% CI, 0.9 to 5.3 for OS; p=0.03). In advanced stage patients (III-IV), the median DFS and OS of patients receiving adjuvant RT with CT was 25 months and 38 months, respectively, compared to 23.5 months and 24.5 months, respectively, in patients receiving adjuvant RT or CT alone (HR, 3.1; 95% CI, 0.6 to 16.0 for DFS; p=0.03); (HR, 3.3; 95% CI, 0.7 to 15.0 for OS; p=0.01). In multivariate analysis, advanced International Federation of Gynecology and Obstetrics (FIGO) stage and suboptimal surgery showed significant association with poor OS.
In patients with early or advanced stage UC, adjuvant CT with RT is associated with improved DFS and OS, as compared to CT or RT alone.
本研究旨在评估子宫癌肉瘤（UC）的临床病理特征、治疗方法及预后情况。
对土耳其三个癌症登记数据库进行回顾性分析，以确定1996年1月1日至2012年12月31日期间诊断为UC的患者。我们收集临床病理数据，以评估对无病生存期（DFS）和总生存期（OS）重要的因素。
共有66例UC患者纳入分析，中位年龄为65.0岁。所有患者的中位生存时间为37.5个月，5年总生存率为59.1%。在接受辅助化疗（CT）联合放射治疗（RT）的早期（I-II期）患者中，中位DFS和OS分别为44个月和55个月，而单独接受辅助RT或CT的患者中位DFS和OS分别为34.5个月和36个月（DFS的风险比[HR]为1.4；95%置信区间[CI]为0.7至3.1；p=0.23；OS的HR为2.2；95%CI为0.9至5.3；p=0.03）。在晚期（III-IV期）患者中，接受辅助RT联合CT的患者中位DFS和OS分别为25个月和38个月，而单独接受辅助RT或CT的患者中位DFS和OS分别为23.5个月和24.5个月（DFS的HR为3.1；95%CI为0.6至16.0；p=0.03）；（OS的HR为3.3；95%CI为0.7至15.0；p=0.01）。多因素分析显示，国际妇产科联盟（FIGO）晚期分期及手术不充分与较差的总生存期显著相关。
与单独使用CT或RT相比，早期或晚期UC患者接受辅助CT联合RT可改善DFS和OS。
